Kenneth Traub - Intermolecular Independent Director
Director
Mr. Kenneth H. Traub is Chairman of the Board of the Company. Mr. Traubs wealth of executive management and board experience and corporate governance awareness from his experience as a senior executive of public companies and his current and past service as a director would allow him to provide valuable advice and guidance to the Board. Mr. Traub has served as a Managing Partner of Raging Capital since December 2016. From 2009 through 2016, Mr. Traub was President and Chief Executive Officer of Ethos Management LLC, and from 2013 through 2016, he served as an Affiliate Partner of Rosemark Capital, a private equity firm. From 1999 until its acquisition by JDS Uniphase Corporationration in 2008, Mr. Traub served as President and Chief Executive Officer of American Bank Note Holographics, Inc., a leading global supplier of optical security devices for the protection of documents and products against counterfeiting. Following the sale of ABNH, he served as Vice President of JDSU, a global leader in optical technologies and telecommunications. In 1994, Mr. Traub cofounded Voxware, Inc., a pioneer in voice over Internet protocol communication technologies, and served as its Executive Vice President and Chief Financial Officer through 1998. From 1988 to 1994, he served as Vice President of TransResources, Inc., a multinational holding company and investment manager since 2018.
| Age | 55 |
| Tenure | 6 years |
| Phone | 408 582-5700 |
| Web | www.intermolecular.com |
Intermolecular Management Efficiency
The company has Return on Asset of 12.76 % which means that on every $100 spent on assets, it made $12.76 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 35.45 %, implying that it generated $35.45 on every 100 dollars invested. Intermolecular's management efficiency ratios could be used to measure how well Intermolecular manages its routine affairs as well as how well it operates its assets and liabilities.The company has 13.65 M in debt with debt to equity (D/E) ratio of 49.1, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Intermolecular has a current ratio of 4.65, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Intermolecular until it has trouble settling it off, either with new capital or with free cash flow. So, Intermolecular's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intermolecular sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intermolecular to invest in growth at high rates of return. When we think about Intermolecular's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Daniel Gill | Asure Software | 53 | |
| Zheng Zhao | Sunlands Technology Group | 41 | |
| Peter Burgess | Lincoln Educational Services | 76 | |
| Lu Lu | Sunlands Technology Group | 34 | |
| Alvin Austin | Lincoln Educational Services | 73 | |
| Brad Burrows | Asure Software | N/A | |
| Patricia Hatter | Qualys Inc | 56 | |
| Howard Schmidt | Qualys Inc | 65 | |
| Scott Wagner | Bill Com Holdings | 50 | |
| Adrian Hennah | Relx PLC ADR | 60 | |
| Lv Lu | Sunlands Technology Group | 35 | |
| Jeffrey Hank | Qualys Inc | 58 | |
| Zheng Du | Sunlands Technology Group | 40 | |
| Celia Currin | Lincoln Educational Services | 66 | |
| Robert Polet | Relx PLC ADR | 59 | |
| Randall Waterfield | Asure Software | 43 | |
| Peter Pace | Qualys Inc | 72 | |
| Ian Fraser | Relx PLC ADR | N/A | |
| Gaoneng Ji | Sunlands Technology Group | 31 | |
| Robert MacLeod | Relx PLC ADR | 56 | |
| Todd Headley | Qualys Inc | 54 | |
Management Performance
| Return On Equity | 35.45 | |||
| Return On Asset | 12.76 |
Intermolecular Leadership Team
Elected by the shareholders, the Intermolecular's board of directors comprises two types of representatives: Intermolecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intermolecular. The board's role is to monitor Intermolecular's management team and ensure that shareholders' interests are well served. Intermolecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intermolecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christian Kramer, President CEO | ||
| Thomas Baruch, Independent Director | ||
| Kenneth Traub, Independent Director | ||
| Jonathan Schultz, Director | ||
| C Neely, CFO, Principal Financial and Accounting Officer | ||
| Bruce McWilliams, Chairman, CEO and Pres | ||
| Matthew Furnas, Director | ||
| Bill Roeschlein, CFO, Principal Financial & Principal Accounting Officer | ||
| Irwin Federman, Independent Director | ||
| Adam Scheer, Director | ||
| George Scalise, Independent Director | ||
| Scot Griffin, Sr. VP of Bus. Operations and Corporate Secretary | ||
| Marvin Burkett, Independent Director |
Intermolecular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intermolecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 35.45 | |||
| Return On Asset | 12.76 | |||
| Profit Margin | 12.89 % | |||
| Operating Margin | (45.02) % | |||
| Current Valuation | 49.2 M | |||
| Shares Outstanding | 49.76 M | |||
| Shares Owned By Insiders | 30.13 % | |||
| Shares Owned By Institutions | 0.37 % | |||
| Number Of Shares Shorted | 4.43 K | |||
| Price To Earning | (3.08) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intermolecular in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intermolecular's short interest history, or implied volatility extrapolated from Intermolecular options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Intermolecular Stock
If you are still planning to invest in Intermolecular check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intermolecular's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |